Merck & Co., Inc. (MRK) vs NOVAVAX INC (NVAX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | MRK | NVAX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.01B | $1.12B |
| Revenue growth (YoY) | ▲ 1.3% | ▲ 64.7% |
| Net income | $18.25B | $440.3M |
| Gross margin | 74.8% | 93.5% |
| Diluted EPS | $7.28 | $2.58 |
| Insider net (6 mo) | −74.8K sh • 9 sells • 0 buys | +122.8K sh • 0 sells • 0 buys |
| Institutional owners | 46 | 38 |
| Institutional value held | $170.91B | $819.92M |
| Next earnings (est.) | Oct 29, 2026 | Around Nov 5, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company operating through two reportable segments, Pharmaceutical and Animal Health, generating total sales of $64.2 billion in 2024, up from $60.1 billion in 2023 and $59.3 billion in 2022. Read more →
About NOVAVAX INC (NVAX)
Novavax, Inc., a Delaware corporation founded in 1987 and headquartered in Gaithersburg, Maryland, is a biotechnology company that discovers, develops and commercializes vaccines to prevent serious infectious diseases. Read more →
Source: SEC EDGAR.